Knight Therapeutics Inc.
GUD.TO
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 2.29% | -3.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.29% | -3.15% | |||
| Cost of Revenue | 16.54% | -1.73% | |||
| Gross Profit | -12.66% | -4.59% | |||
| SG&A Expenses | -3.20% | 0.80% | |||
| Depreciation & Amortization | -7.35% | -3.93% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.21% | -1.90% | |||
| Operating Income | -190.04% | -28.49% | |||
| Income Before Tax | 1,161.93% | -14.45% | |||
| Income Tax Expenses | -632.75% | -80.24% | |||
| Earnings from Continuing Operations | 12,209.47% | 104.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12,209.47% | 104.39% | |||
| EBIT | -190.04% | -28.49% | |||
| EBITDA | -62.06% | -5.76% | |||
| EPS Basic | 12,616.67% | 104.29% | |||
| Normalized Basic EPS | 3,425.00% | 61.29% | |||
| EPS Diluted | 11,850.00% | 104.11% | |||
| Normalized Diluted EPS | 3,412.50% | 61.29% | |||
| Average Basic Shares Outstanding | -0.59% | -0.19% | |||
| Average Diluted Shares Outstanding | -0.19% | -0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||